

UK OFFERS GREAT SCOPE FOR RESPIRI TO DEVELOP KEY PARTNERSHIPS

Respiri is in an advantageous position to partner and collaborate in the UK with its asthma monitoring system.

Discussions held with leaders in the UK provide an exciting foundation to accelerate our commercialisation plans.

- Recent UK reports: ‘Why Asthma Still Kills, The National Review of Asthma Deaths (NRAD)’ & ‘Connected Asthma: How Technology Will Transform Asthma Care’ (Asthma UK) stress the need for improved self-management of asthma and how technology enabled asthma management could transform asthma care.
- Leading UK physicians and scientists in world-class UK hospitals have deployed Respiri’s algorithm technology to detect and measure wheeze. Dr Mark L Levy, the clinical lead on NRAD has, together with other prominent physicians, published research using Respiri’s digital wheeze technology.

Kay Boycott, Chief Executive, Asthma UK referred to the NRAD Report as delivering “*a damning assessment of current routine practice in asthma care*”; and the report noted that: “*people with asthma know that there is nothing as frightening as being unable to breathe... the review found that the simple elements of basic care that prevent asthma attacks were not being delivered*”.

Importantly Asthma UK wrote:

“Almost three quarters of people with asthma in the UK would like to see a mobile health device made available that would help them monitor their asthma.”

THE MOBILE HEALTH SYSTEM that... MONITORS THEIR SYMPTOMS DOES EXIST...

IT’S CALLED AIRSONEA®, from RESPIRI LIMITED.

AIRSONEA TICKS ALL THE BOXES

- ✓ With first mover advantage, it has the advanced technology platform to help transform current asthma management and the relationship between patient and healthcare providers. AirSonea supports a shift towards supporting greater self-management of asthma and less reliance on overstretched clinical services.
- ✓ Designed as an over the counter device it will benefit consumers, both children and adults, diagnosed with asthma who wish to monitor their health at home. The convenient and easy to use AirSonea technology platform detects and measures wheeze, helps track triggers and symptoms, provides reminders to patients and documents medication usage.
- ✓ Provides physicians with information of how their patients are doing in between visits enabling them to adjust therapies. The findings of the UK research “show the need for genuine co-production in the development of any mHealth solutions between clinicians and the people who will use them every day for the rest of their lives. People with asthma span all ages and lifestyles – they don’t tolerate a one-size fits all approach in other aspects of their life, and mHealth solutions are going to be no different”.

Respiri's AirSonea sensor device and app technology is a "monitoring" product to be used by patients that have been diagnosed with asthma rather than a "diagnostic" device. This enhances our opportunities for collaboration with global industry leaders and delivers multiple revenue streams including consumer, physicians & healthcare workers, payers, telemedicine and employers.

Peter Vaughan
Company Secretary

Ph: 1800 476 632